Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has reached a significant milestone in protecting the commercial identity of its lead product candidate. The company announced that it received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) on September 2, for trademarks associated with its abuse-deterrent fentanyl transdermal system. This advancement is crucial as it moves the company one step closer to securing exclusive rights to the brand names under which it intends to market the product.
The Notice of Publication indicates that the trademarks will be listed in the USPTO Trademark Official Gazette, triggering a 30-day opposition period. If no third-party objections are raised during this period, the USPTO is expected to issue a Notice of Allowance, which would pave the way for final trademark registration. This procedural step is vital for Nutriband to safeguard its intellectual property and establish a strong market presence for its innovative patch.
The fentanyl patch in question incorporates Nutriband's proprietary AVERSA™ abuse-deterrent technology. This technology is designed to deter abuse and misuse of fentanyl, a potent opioid, and to reduce the risk of accidental exposure. Given the ongoing opioid crisis, the development of such abuse-deterrent formulations is of paramount importance. The product has the potential to address a critical public health need while also offering significant commercial opportunities.
Nutriband has stated that the product could achieve peak annual U.S. sales of $80 million to $200 million. This projection underscores the market potential for a safer fentanyl delivery system, especially as healthcare providers and regulators seek ways to mitigate opioid-related harms. The company's AVERSA™ technology is already protected by patents issued in 46 countries, providing a robust intellectual property foundation for the product's global commercialization.
The significance of this trademark advancement extends beyond legal protection. It signals Nutriband's commitment to building a recognizable and trusted brand for its abuse-deterrent fentanyl patch. As the company progresses through regulatory and commercial development, securing trademarks early helps establish a competitive edge and facilitates marketing efforts upon product approval.
This development also highlights the growing interest in abuse-deterrent technologies within the pharmaceutical industry. With the FDA encouraging the development of such formulations to combat opioid abuse, products like Nutriband's fentanyl patch are positioned to meet regulatory and market demands. The company's progress in protecting its trademarks reflects a broader trend toward prioritizing safety features in opioid medications.
Investors and stakeholders are likely to view this news positively, as it reduces the risk of brand infringement and strengthens the company's overall business strategy. While regulatory approval and commercial launch remain future milestones, the trademark advancement is a tangible step forward in Nutriband's journey to bring a differentiated product to market.
For more information about Nutriband and its pipeline, visit the company's website or its newsroom at https://ibn.fm/NTRB. The full press release is available at https://ibn.fm/p1wVE.
